Cabaletta Bio/CABA

$10.20

1.49%
-
1D1W1MYTD1YMAX

About Cabaletta Bio

Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Ticker

CABA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Steven Nichtberger

Employees

118

Headquarters

Philadelphia, United States

Cabaletta Bio Metrics

BasicAdvanced
$515M
Market cap
-
P/E ratio
-$1.73
EPS
2.47
Beta
-
Dividend rate
$515M
2.47131
$26.35
$9.02
1.1M
12.657
-44.7%
-49.06%
-48.55%
2.322
2.323
4%

What the Analysts think about Cabaletta Bio

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 9 analysts.
229.02% upside
High $50.00
Low $25.00
$10.20
Current price
$33.56
Average price target

Cabaletta Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$25M
20.19%
Profit margin
0%
NaN%

Cabaletta Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.23%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.37
-$0.37
-$0.46
-$0.51
-
Expected
-$0.44
-$0.40
-$0.39
-$0.48
-$0.55
Surprise
-16.38%
-8.33%
17.23%
7.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cabaletta Bio stock?

Cabaletta Bio (CABA) has a market cap of $515M as of May 30, 2024.

What is the P/E ratio for Cabaletta Bio stock?

The price to earnings (P/E) ratio for Cabaletta Bio (CABA) stock is 0 as of May 30, 2024.

Does Cabaletta Bio stock pay dividends?

No, Cabaletta Bio (CABA) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Cabaletta Bio dividend payment date?

Cabaletta Bio (CABA) stock does not pay dividends to its shareholders.

What is the beta indicator for Cabaletta Bio?

Cabaletta Bio (CABA) has a beta rating of 2.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Cabaletta Bio stock price target?

The target price for Cabaletta Bio (CABA) stock is $33.56, which is 229.02% above the current price of $10.2. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cabaletta Bio stock

Buy or sell Cabaletta Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing